Scoop: Metagenomi is preparing for an IPO this fall, in what could jumpstart a wave of public offerings

Gene-edit­ing biotech Metageno­mi is prepar­ing to go pub­lic and is work­ing with the in­vest­ment bank JP Mor­gan on a po­ten­tial list­ing this fall, ac­cord­ing to peo­ple fa­mil­iar with the com­pa­ny’s plans.

If Metageno­mi goes pub­lic, it would be one of on­ly about a dozen biotech IPOs this year, though like­ly one of the largest. It has al­ready brought in more than $400 mil­lion in ven­ture cap­i­tal fund­ing and from bio­phar­ma part­ner­ships, an amount that puts it in the same class of fundrais­ing as oth­er sig­nif­i­cant IPOs of 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.